Full-Time

Key Account Manager Biopharma

Danaher Corporation

Danaher Corporation

10,001+ employees

Water quality, diagnostics, product identification solutions

No salary listed

Frankfurt, Germany

Hybrid

Category
Sales & Account Management (1)
Required Skills
Sales
Forecasting
Salesforce
Requirements
  • Bachelor’s degree in Life Sciences, Bioengineering, Biotechnology or related scientific field; advanced degree (MSc/PhD) or MBA is a plus.
  • 5–7+ years of experience in Key Account Management / Strategic Sales within life science tools, Biopharma, Clinical Research or adjacent high-tech markets.
  • Experience selling into Biopharma environments (e.g., biologics, cell & gene therapy, vaccines) and/or regulated laboratories (GxP).
  • Proven ability to navigate complex organizations and engage stakeholders across scientific, operational, procurement and executive functions; strong collaboration skills and ability to lead cross-functional teams without direct authority.
  • Strong business acumen with a consultative, value-selling approach; analytical and structured way of working.
  • Travel up to 50% travel across Central Europe.
Responsibilities
  • Own the account strategy and territory plan for top BioPharma and Biotech companies within Central Europe to Biopharma and Clinical Research priorities (e.g., process development, QC/QA, translational research, imaging core facilities).
  • Build and expand long-term executive relationships and a strong KOL network; map stakeholders, influence structures and buying centers.
  • Drive opportunity identification, qualification and pipeline management across the portfolio; ensure accurate funnel hygiene and forecasting (e.g., Salesforce).
  • Lead the end-to-end sales process: customer discovery, solution design (with Product Specialists/Applications), value-based proposals, quoting, negotiation and commercial closing.
  • Coordinate cross-functionally (Product Specialists, Applications, Service, Marketing) to deliver best-in-class customer experience (demos, evaluations, implementation handover, service escalation) and execute account penetration/retention and ABM activities with measurable follow-up.
Desired Qualifications
  • Advanced degree (MSc/PhD) or MBA is a plus.
  • Experience with CRM/ERP tools (e.g., Salesforce and SAP) preferred.
  • Knowledge of microscopy/imaging workflows applied to Biopharma and Clinical Research (e.g., high-content imaging, digital pathology, image analysis, automation)

Danaher focuses on three main areas: water quality, product identification, and diagnostics, serving municipal, industrial, and healthcare customers. In water quality, it supplies precision instruments and purification technologies to analyze, treat, and manage water across various settings. In product identification, it leads in laser marking, coding, engraving, packaging solutions, and color science to ensure accurate labeling and product traceability. In diagnostics, it provides automated tools and software for medical testing and point-of-care care, all guided by the Danaher Business System that drives continuous improvement; the company aims to improve water safety, supply-chain traceability, and healthcare outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Washington DC, District of Columbia

Founded

1969

Simplify Jobs

Simplify's Take

What believers are saying

  • Masimo $9.9B acquisition adds $1.5B sales and $530M EBITDA by 2027.
  • Biopharma spending stabilizes in 2026, boosting biotech tools demand.
  • $5.3B 2025 free cash flow funds growth amid sector recovery.

What critics are saying

  • FTC blocks Masimo deal in 3-9 months, delaying diagnostics expansion.
  • Cepheid respiratory weakness erodes 3-6% 2026 revenue guidance.
  • China's 11% revenue softens from trade tensions, losing share to Thermo Fisher.

What makes Danaher Corporation unique

  • Danaher Business System drives continuous improvement across acquired companies.
  • Biotechnology, life sciences, and diagnostics divisions integrate for end-to-end innovation.
  • Provides picks-and-shovels tools enabling biopharma research without drug risks.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Danaher Corporation who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Limited

Paid Vacation

Paid Holidays

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Hybrid Work Options

Stock Options

Company Equity

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Fertility Treatment Support

Family Planning Benefits

Adoption Assistance

Childcare Support

Elder Care Support

Parental Leave

Parental Leave

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Employee Discounts

Meal Benefits

Relocation Assistance

Pet Insurance

Commuter Benefits

Bereavement Leave

Training Programs

Educational Allowance

Employee Referral Bonus

Performance Bonus

Profit Sharing

Healthcare Savings Account

Flexible Spending Account

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-11%

2 year growth

-11%
CEO India Magazine
Mar 25th, 2026
General Electric CEO H. Lawrence Culp Jr.: the leader behind one of the greatest corporate turnarounds.

General Electric CEO H. Lawrence Culp Jr.: the leader behind one of the greatest corporate turnarounds. hemlataMarch 25, 20264 Mins read Introduction. The transformation of General Electric (GE) over the past few years is often cited as one of the most significant corporate turnarounds in modern business history. At the center of this transformation is General Electric CEO H. Lawrence Culp Jr., a leader who brought clarity, discipline, and a long-term vision to a company struggling with complexity and declining performance. When Larry Culp stepped into the role in 2018, GE was facing mounting debt, operational inefficiencies, and a loss of investor confidence. It was no longer the dominant industrial powerhouse it once was. Many believed the company's best days were behind it. However, through a structured and focused approach, he initiated a transformation that would redefine GE's future. His leadership journey reflects a broader shift in global business - where simplicity, accountability, and operational excellence matter more than aggressive expansion. Similar to the strategic discipline seen in Thomas Schinecker's Roche CEO leadership approach, Culp's methods highlight how strong execution can rebuild even the most complex organizations. Early life and academic foundation. H. Lawrence Culp Jr., often referred to as Larry Culp, was born in 1963 in the United States. From an early age, he demonstrated a strong inclination toward structured thinking and leadership. He pursued his undergraduate education at Washington College, followed by an MBA from Harvard Business School. His academic journey provided him with: * A strong foundation in business strategy * Analytical and financial expertise * Leadership and management capabilities These early experiences shaped his disciplined and data-driven leadership style. Career breakthrough at Danaher: building a reputation. Before joining GE, Larry Culp built his reputation at Danaher Corporation, where he served as CEO from 2000 to 2014. During his leadership: * Danaher's revenue and market value grew significantly * The company became a model for operational excellence * He implemented the Danaher Business System (DBS) Understanding the Danaher Business System. DBS is a structured management philosophy that focuses on: * Continuous improvement * Lean operations * Performance measurement * Problem-solving through data This system transformed Danaher into a highly efficient organization and became a benchmark in the corporate world. More importantly, DBS became the foundation of Culp's leadership philosophy - a philosophy he later brought to GE. A historic appointment at General Electric. In 2018, Larry Culp became CEO of General Electric, marking a historic moment as he was the first external leader in the company's long history. At the time, GE was facing serious challenges: * Over $100 billion in debt * Declining stock value * A highly complex organizational structure * Weak operational performance His appointment signaled a major shift - from traditional leadership to a more disciplined and execution-focused approach. Diagnosing the Problem: understanding GE's challenges. Before implementing changes, Culp focused on understanding the root causes of GE's struggles. Key issues identified: * Over-diversification across too many industries * Lack of operational discipline * Poor capital allocation decisions * Complex and inefficient structures Instead of making quick changes, he took a systematic approach - analyzing data, identifying inefficiencies, and prioritizing actions. The turnaround strategy: A step-by-step transformation. The leadership of General Electric CEO H. Lawrence Culp Jr. is best understood through his multi-layered turnaround strategy. 1. Simplification of the organization. GE had become overly complex, with multiple business units and layers of management. Culp focused on: * Removing unnecessary complexity * Flattening organizational structures * Improving communication and accountability This simplification allowed faster decision-making and better execution. 2. Financial discipline and debt reduction. One of his top priorities was fixing GE's financial health. Key actions: * Selling non-core assets * Reducing debt * Improving cash flow * Strengthening the balance sheet This disciplined approach helped restore investor confidence. 3. Strategic focus on core businesses. Instead of trying to be everywhere, GE narrowed its focus to key sectors: * Aviation * Healthcare * Energy This strategic clarity improved operational efficiency and long-term growth potential. 4. Breaking up GE: A bold decision. One of the most significant decisions under his leadership was restructuring GE into separate companies. This move aimed to: * Unlock shareholder value * Allow each business unit to operate independently * Improve focus and agility This strategy reflects modern leadership thinking, similar to Ted Decker's Home Depot leadership, where simplification and focus drive success. 5. Implementation of lean management and operational excellence. Culp introduced lean management practices inspired by DBS. Impact: * Increased productivity * Reduced waste * Improved operational efficiency Employees were encouraged to focus on continuous improvement and measurable outcomes. Leadership style: discipline meets clarity. Larry Culp's leadership style stands out for its simplicity and effectiveness. Key characteristics: 1. Data-Driven decision making. Every decision is backed by data and analysis. 2. Transparency. He maintains clear communication with stakeholders. 3. Accountability. Leaders are responsible for results, not just plans. 4. Long-Term focus. He prioritizes sustainable growth over short-term gains. This approach aligns with leadership philosophies seen in Caterpillar CEO Jim Umpleby's strategy, where operational discipline and long-term thinking are central. Challenges during the turnaround. Transforming a company like GE comes with significant challenges. 1. Legacy systems and culture. Changing long-established systems and mindsets required time. 2. Investor expectations. Stakeholders expected quick results, increasing pressure. 3. Global economic factors. External factors such as economic downturns affected performance. 4. Industry competition. GE operates in highly competitive industries. Despite these challenges, consistent progress has been achieved. Impact and results of the transformation. Under Culp's leadership, GE has shown measurable improvements: * Significant reduction in debt * Improved cash flow and financial stability * Stronger performance in core sectors * Renewed investor confidence The transformation is ongoing, but the results demonstrate the effectiveness of his strategy. Business lessons from Larry Culp's leadership. The journey of GE's transformation offers valuable lessons: 1. Simplify to succeed. Complexity can hinder growth - simplicity enables it. 2. Focus on core strengths. Concentrating on key areas leads to better results. 3. Discipline is non-negotiable. Strong financial and operational discipline is essential. 4. Take bold decisions. Breaking up GE required courage and vision. 5. Think long-term. Sustainable success takes time. Sustainability and innovation at GE. GE is increasingly focusing on sustainability and innovation. Key areas: * Renewable energy solutions * Advanced aviation technology * Healthcare innovation These initiatives position GE as a forward-looking company. For deeper insights into global business transformation and leadership strategies, explore: Future outlook: what lies ahead for GE. The future strategy focuses on: * Independent and focused business units * Continuous innovation * Operational excellence * Sustainable growth GE is evolving into a more agile and efficient organization. Conclusion. The journey of General Electric CEO H. Lawrence Culp Jr. is a masterclass in leadership and transformation. By focusing on simplicity, discipline, and execution, he has led one of the most remarkable corporate turnarounds in recent history. His leadership proves that even the most complex organizations can be rebuilt with the right strategy and mindset. For business leaders, entrepreneurs, and professionals, his journey offers a powerful blueprint for long-term success.

Yahoo Finance
Mar 24th, 2026
Danaher reports Q4 revenue of $6.84B as bioprocessing drives strong finish to the year

Danaher reported Q4 revenues of $6.84 billion, up 4.6% year on year, meeting analysts' expectations. The life sciences company delivered strong performance across its portfolio, particularly in bioprocessing, with improved momentum in diagnostics and life sciences divisions. The research tools and consumables sector overall posted satisfactory Q4 results, with the 10 tracked stocks beating consensus revenue estimates by 1.2%. However, share prices have struggled, declining 18.9% on average since latest earnings. The sector faces challenges including high R&D costs and sensitivity to research funding cycles, but benefits from recurring revenue streams and opportunities in emerging fields like synthetic biology and AI-driven laboratory automation. CEO Rainer Blair highlighted disciplined execution that exceeded margin, earnings and cash flow expectations.

Yahoo Finance
Mar 20th, 2026
Danaher stock drops 30% from highs, presenting entry point into healthcare compounder

Danaher Corporation has drawn investor attention following a pullback of over 30% from its 52-week highs, creating what analysts view as an attractive entry point. The healthcare and life sciences company, known for its Danaher Business System, generates approximately $24 billion in revenue with operating margins near 18%. Whilst near-term headwinds have emerged from a slowdown in biotech funding amongst smaller labs, this pressure is considered cyclical rather than structural. Danaher maintains strong profitability with a healthy balance sheet, including a debt-to-equity ratio of around 0.35. The company remains positioned in long-term secular growth trends including biologics manufacturing, diagnostics and life sciences research. Analysts suggest the recent decline offers an opportunity to acquire shares of a proven compounder at a relative discount, with favourable risk-reward prospects as biotech funding cycles normalise.

Schaeffer's Investment Research
Feb 20th, 2026
Geopolitical Tensions Resurface Amid Volatile Week

Geopolitical tensions resurface amid volatile week. The S&P 500 and Nasdaq boast healthy weekly gains. Assistant Editor Feb 20, 2026 at 2:09 PM Despite Tuesday's rough start, all three major indexes closed higher, the Nasdaq Composite (IXIC) snapping its four day-losing streak. Stocks held steady on Wednesday after receiving a boost from big tech gains, while the Federal Reserve's January meeting minutes held investor attention. On Thursday, the Dow Jones Industrial Average (DJI) and S&P 500 Index (SPX) both snapped three-day win streaks, while the Nasdaq also faced trouble; these losses slid right past traders as focus remained on geopolitical tensions and weekly jobless claims. The Nasdaq and S&P 500 are pacing for weekly gains, after the Supreme Court dismissed President Donald Trump's tariffs and lifted Wall Street's spirits. Stock movers this week. There were plenty of headlines for investors to unpack over the holiday-shortened week. Norwegian Cruise Line Holdings (NCLH) popped after reports that Elliott Investment Management has built an over 10% stake. In M&A news, Masimo (MASI) stock soared after reports that it will be acquired by Danaher (DHR) for $10 billion, while Hims & Hers Health (HIMS) announced its $1.15 billion acquisition of Australian digital health company Eucalyptus. In biotech news this week, the U.S. Food & Drug Administration (FDA) accepted Moderna's (MRNA) flu vaccine application for review, while Grail (GRAL) stock plummeted after the company's three-year cancer screening trial failed to meet its main goal. Meanwhile, Walmart's (WMT) disappointed earnings outlook contributed to pessimism on Thursday. Commodities, rare earths in focus. Rising oil prices were a highlight this week amid U.S.-Iran tensions, with options bulls targeting the United States Oil Fund (USO). Meanwhile, Devon Energy (DVN) tapped a 17-month high after strong fourth-quarter results, while Melius Research upgraded Chevon (CVX), citing exploration upside. Even further, gold mining name Newmont (NEM) continued to charge higher before its fourth-quarter report. On the flip side, rare earths stock MP Materials (MP) plummeted to a one-month low. As goes february. The final week of the month is jam packed with key earnings reports, delayed economic data, speeches from several Federal Reserve officials, and more. For now, Schaeffer's Senior V.P. of Research Todd Salamone says to keep your eye on these S&P 500 names, while Senior Quantitative Analyst Rocky White breaks down Wall Street's "fear gauge."

Yahoo Finance
Feb 17th, 2026
Danaher signals bioprocessing stabilisation, exceeds expectations despite market challenges

Danaher Corporation, a healthcare and life sciences company, showed signs of stabilisation in its bioprocessing segment during Q4 2025, according to ArrowMark Partners' Meridian Hedged Equity Fund investor letter. The company's shares rose after results exceeded expectations and management reaffirmed forward guidance. Danaher operates through biotechnology, life sciences and diagnostics segments. The company reported 2025 sales of $24.6 billion with 2% core revenue growth. As of 13 February 2026, shares traded at $212.58, giving it a market capitalisation of $150.16 billion. Meridian Funds holds Danaher for its competitive positioning in growing end-markets, its bioprocessing franchise and consistent free cash flow generation. The fund noted management's confidence in portfolio resilience despite broader market challenges.